Circulating tumor DNA - from biology to potential clinical applications in diffuse large B-cell lymphomas.

IF 2.9 Q2 ONCOLOGY

Wspolczesna Onkologia-Contemporary Oncology Pub Date : 2025-01-01 Epub Date: 2025-05-09 DOI:10.5114/wo.2025.150452

Krzysztof Lewandowski, Kinga Gwóźdź-Bąk

{"title":"Circulating tumor DNA - from biology to potential clinical applications in diffuse large B-cell lymphomas.","authors":"Krzysztof Lewandowski, Kinga Gwóźdź-Bąk","doi":"10.5114/wo.2025.150452","DOIUrl":null,"url":null,"abstract":"<p><p>During the last 20 years, significant progress has been made in understanding the biology of cancer cells. Assessment of the molecular profile of neoplastic cells collected by tissue biopsy using next-generation sequencing techniques makes it possible to diagnose the specific diffuse large B-cell lymphoma subtype and to personalize the therapy applied through the rational use of molecularly targeted drugs. Similar to the other methods of biopsy material evaluation, this method has some limitations. It may fail in cases when tissue biopsies do not fully capture intratumor genetic heterogeneity. For this reason, research has been undertaken to find new laboratory methods to study the genetic heterogeneity of cancer cells and to characterize all lymphoma cells at once, regardless of the origin of the tumor cells and the stage of its transformation. One promising diagnostic approach is the evaluation of total free circulating DNA, including circulating tumor DNA, using molecular biology techniques.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"150-158"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224274/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wspolczesna Onkologia-Contemporary Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2025.150452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

During the last 20 years, significant progress has been made in understanding the biology of cancer cells. Assessment of the molecular profile of neoplastic cells collected by tissue biopsy using next-generation sequencing techniques makes it possible to diagnose the specific diffuse large B-cell lymphoma subtype and to personalize the therapy applied through the rational use of molecularly targeted drugs. Similar to the other methods of biopsy material evaluation, this method has some limitations. It may fail in cases when tissue biopsies do not fully capture intratumor genetic heterogeneity. For this reason, research has been undertaken to find new laboratory methods to study the genetic heterogeneity of cancer cells and to characterize all lymphoma cells at once, regardless of the origin of the tumor cells and the stage of its transformation. One promising diagnostic approach is the evaluation of total free circulating DNA, including circulating tumor DNA, using molecular biology techniques.

查看原文本刊更多论文

循环肿瘤DNA -从生物学到弥漫性大b细胞淋巴瘤的潜在临床应用。

在过去的20年里，在了解癌细胞的生物学方面取得了重大进展。利用新一代测序技术对组织活检收集的肿瘤细胞的分子谱进行评估，可以诊断特异性弥漫性大b细胞淋巴瘤亚型，并通过合理使用分子靶向药物来个性化治疗。与其他活检材料评估方法类似，该方法有一定的局限性。当组织活检不能完全捕获肿瘤内遗传异质性时，它可能会失败。因此，研究人员一直在寻找新的实验室方法来研究癌细胞的遗传异质性，并同时表征所有淋巴瘤细胞，而不考虑肿瘤细胞的起源和转化阶段。一种有前途的诊断方法是利用分子生物学技术评估总游离循环DNA，包括循环肿瘤DNA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wspolczesna Onkologia-Contemporary Oncology 医学-肿瘤学

CiteScore

3.10

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Contemporary Oncology is a journal aimed at oncologists, oncological surgeons, hematologists, radiologists, pathologists, radiotherapists, palliative care specialists, psychologists, nutritionists, and representatives of any other professions, whose interests are related to cancer. Manuscripts devoted to basic research in the field of oncology are also welcomed.